109 related articles for article (PubMed ID: 16187694)
1. Torcetrapib + atorvastatin (Pfizer).
Burnett JR
Curr Opin Investig Drugs; 2005 Sep; 6(9):944-50. PubMed ID: 16187694
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
5. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
6. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
8. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
[TBL] [Abstract][Full Text] [Related]
9. Torcetrapib/atorvastatin combination therapy.
Bays H; McKenney J; Davidson M
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):789-820. PubMed ID: 16181026
[TBL] [Abstract][Full Text] [Related]
10. Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.
Zareba G
Drugs Today (Barc); 2006 Feb; 42(2):95-102. PubMed ID: 16541186
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
12. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
13. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
15. The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
Bolewski A; Lipiecki J; Plewa R; Burchardt P; Siminiak T
Cardiology; 2008; 111(2):140-6. PubMed ID: 18376126
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
[TBL] [Abstract][Full Text] [Related]
17. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
18. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Clark RW
Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
[TBL] [Abstract][Full Text] [Related]
19. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Masson D
Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
